ARD-2128

• Description :

  ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer[1].

• UNSPSC :

  12352005

• Target :

  Androgen Receptor; PROTACs

• Type :

  Reference compound

• Related Pathways :

  PROTAC; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ard-2128.html

• Purity :

  99.40

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(N[C@H]1C(C)(C)[C@H](OC2=CC=C(C#N)C(Cl)=C2)C1(C)C)C3=CC=C(N4CCN(CC5CCN(C6=CC7=C(C(N(C(CC8)C(NC8=O)=O)C7=O)=O)C=C6)CC5)CC4)C=C3

• Molecular Formula :

  C45H50ClN7O6

• Molecular Weight :

  820.37

• References & Citations :

  [1]Han X, et al. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer [published online ahead of print, 2021 Aug 25]. J Med Chem. 2021;10.1021/acs.jmedchem.1c00882.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2222111-87-5]